Jefferies Initiates Coverage of Q32 Bio with Buy
Fintel reports that on September 28, 2026, Jefferies initiated coverage of Q32 Bio (NASDAQCM:QTTB) (DB:DB0) with a Buy recommendation.
On the day of the rating action, September 28, 2026, the latest close for Q32 Bio was $9.23. This followed a pre-action close of $8.77 on September 25, 2026. Over the preceding periods, the stock experienced a downward trend. Specifically, the one-week price change was -11.84% from a baseline close of $10.47 on September 21, 2026. Looking further back, the one-month price change was -38.59% from a baseline close of $15.03 on August 28, 2026.
Separately from Jefferies' individual rating, the broader consensus target price data for the company shows significant upside potential. As of September 15, 2026, the current consensus target mean was $41.82, and the median target was $36.72. This mean target represents an implied change of +353.09% from the stock's trading levels. The prior consensus target mean, recorded on August 28, 2026, was also $41.82, representing a consensus target revision of 0.00%.
Q32 Bio last reported its quarterly earnings on August 5, 2026. For the quarter, the company reported an actual EPS of -0.43, which compared to an estimated EPS of -0.553. Both actual revenue and estimated revenue for the period were reported at $0.00.
In terms of overall analyst sentiment, the current recommendation period as of September 1, 2026, shows a total of 12 recommendations. This includes 3 strong buy, 8 buy, 1 hold, 0 sell, and 0 strong sell ratings, resulting in a positive recommendation percentage of 91.7% and a hold percentage of 8.3%. This represents a slight shift from the prior recommendation period as of August 1, 2026, which had a total of 11 recommendations (3 strong buy, 7 buy, 1 hold, 0 sell, and 0 strong sell), translating to 90.9% positive and 9.1% hold ratings.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 28, 2026 | Jefferies | Buy | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.